{"title":"PECULIARITIES OF THE CLINICAL COURSE OF NON-ALCOHOLIC STEATOHEPATITIS AND STEATOSIS OF THE LIVER AT COMORBID WITH CHRONIC KIDNEY DISEASE I-III STAGE","authors":"А.А. Antoniv","doi":"10.24061/1727-4338.XX.1.75.2021.1","DOIUrl":null,"url":null,"abstract":"Purpose - to establish clinical peculiarities of the clinical course of the liver nonalcoholic steatosis (NALS) and steatohepatitis (NASH) at comorbidity with chronickidney disease (CKD) (chronic pyelonephritis) I-III stage.Material and methods. We have examined 444 patients: 84 patients with non-alcoholicadipose liver disease (NAALD) with obesity I degree (I group), containing 2 subgroups -32 patients with NALS and 52 patients with NASH; 270 NAALD patients with comorbidobesity I degree and CKD I-III stages (group 2), including 110 patients with NALS and160 patients with NASH. The control group consisted of 90 patients with CKD I-III stagewith normal body weight.Results. Clinical peculiarities of the liver non-alcoholic steatosis at comorbidity withCKD are a significant prevalence, in comparison with the clinical course without kidneypathology, of the frequency of manifestation of astheno-vegetative (70,9% to 40,6%),dyspeptic (33,6% to 18,8%), cholestatic (30,9% to 15,6%) syndromes, hepatomegaly(97,3% - 71,8%), predominance of steatosis II and III degree (47,2% and 31,8% to 25,0% and 15, 6% at NALS without kidney pathology). High frequency of asthenovegetative(98,1% to 61,5%) syndrome, dyspepsia (79,4% to 59,6%), discomfort in the rightsubcostal area (84,4% to 32,7%), cholestasis (37,5% to 17,3%), hepatomegaly (100,0%to 86,5%), prevalence of steatosis II and III degree (58,1% and 26,3% to 32,7% and11,5% at NASH without kidney pathology) is peculiar for non-alcoholic steatohepatitisclinical course at comorbidity with CKD as compared to the course without kidneypathology.Conclusions. Thus, the clinical course of nonalcoholic steatosis and steatohepatitis atcomorbidity with obesity and chronic kidney disease (CKD) is characterized by higherfrequency and intensity of the clinical and biochemical syndromes.","PeriodicalId":12291,"journal":{"name":"Experimental pathology","volume":"122 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24061/1727-4338.XX.1.75.2021.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose - to establish clinical peculiarities of the clinical course of the liver nonalcoholic steatosis (NALS) and steatohepatitis (NASH) at comorbidity with chronickidney disease (CKD) (chronic pyelonephritis) I-III stage.Material and methods. We have examined 444 patients: 84 patients with non-alcoholicadipose liver disease (NAALD) with obesity I degree (I group), containing 2 subgroups -32 patients with NALS and 52 patients with NASH; 270 NAALD patients with comorbidobesity I degree and CKD I-III stages (group 2), including 110 patients with NALS and160 patients with NASH. The control group consisted of 90 patients with CKD I-III stagewith normal body weight.Results. Clinical peculiarities of the liver non-alcoholic steatosis at comorbidity withCKD are a significant prevalence, in comparison with the clinical course without kidneypathology, of the frequency of manifestation of astheno-vegetative (70,9% to 40,6%),dyspeptic (33,6% to 18,8%), cholestatic (30,9% to 15,6%) syndromes, hepatomegaly(97,3% - 71,8%), predominance of steatosis II and III degree (47,2% and 31,8% to 25,0% and 15, 6% at NALS without kidney pathology). High frequency of asthenovegetative(98,1% to 61,5%) syndrome, dyspepsia (79,4% to 59,6%), discomfort in the rightsubcostal area (84,4% to 32,7%), cholestasis (37,5% to 17,3%), hepatomegaly (100,0%to 86,5%), prevalence of steatosis II and III degree (58,1% and 26,3% to 32,7% and11,5% at NASH without kidney pathology) is peculiar for non-alcoholic steatohepatitisclinical course at comorbidity with CKD as compared to the course without kidneypathology.Conclusions. Thus, the clinical course of nonalcoholic steatosis and steatohepatitis atcomorbidity with obesity and chronic kidney disease (CKD) is characterized by higherfrequency and intensity of the clinical and biochemical syndromes.